Home
Life Sciences
Pharmaceutical
Therapy
Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Therapy

Summary

Table of Contents

Data Series

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Publication date: August 2010

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets Summary GBI Research’s Therapeutic Analysis report, “Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets”, provides in-depth analysis of unmet needs,...

Search ReportLinker

The Largest Collection of Market Research Reports

» 1.2 Million Industry Reports
» 450,000 Company Profiles

» 850,000 Market Briefings
» 40,000 Country Guides

From +200,000 authoritative sources

Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets

Summary

GBI Research’s Therapeutic Analysis report, “Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets”, provides in-depth analysis of unmet needs, drivers and barriers that impact the global urological disorders market. This pharmaceutical and healthcare report analyzes the markets for urological disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research finds that the urological disorders market will continue to grow moderately, largely due to increase in aging population and increase in awareness of indications such as UI, BPH and UTI. The prime reason for slow growth of the market will be a series of patent expiries of the top selling blockbusters across all the markets. Particularly in BPH, the entry of generics coupled with the patent expirations of Flomax, Uroxatral (in US) and Avodart, three of the best selling drugs in the BPH market, is expected to pull down the market in terms of value in the future. However, the patent expiries will not result in significant market value loss due to the low price differential between branded and generics.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

- Annualized market data for the urological disorders market from 2001 to 2009, forecast forward to 2016.
- Analysis of the leading therapeutic segments, including Urinary Incontinence (UI), Benign Prostatic Hyperplasia (BPH) and Urinary Tract Infections (UTI).
- Analysis of the urological disorders market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.
- Market characterization of the urological disorders market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Allergen Inc, Astellas Pharma, Pfizer Inc, Novexel SA, Eli Lilly and Company, GSK, Sanofi-- Aventis, Johnson and Johnson and Protox Therapeutics, Inc.
- Key M&A activities, licensing agreements that have taken place between 2004 and mid-2010 in the global urological disorders market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

Global Therapy Industry

1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 7
2 Global Urological Disorders Market: Introduction 10
2.1 GBI Research Report Guidance 11
3 Global Urological Disorders Market: Market Overview 12
3.1 Introduction 12
3.2 Revenue Forecasts for the Global Urological Disorders Market 13
3.2.1 Sales Value 13
3.2.2 Annual Cost of Therapy 14
3.2.3 Treatment Usage Patterns 15
3.2.4 Generics’ Share in the Global Urological Disorders Market 20
3.3 Urological Disorders Market Drivers 22
3.3.1 Steady Increase in the UI and BPH Prevalence Population 22
3.3.2 Rapid Uptake of Branded Products due to Better Efficacy in BPH 22
3.3.3 Patent Expiries of Branded Drugs Will Make Them More Affordable 22
3.4 Urological Disorders Market Restraints 23
3.4.1 Unwillingness to Seek Medical Help for UI 23
3.4.2 Patent Expiries of Major Blockbusters Including Detrol, Flomax, Levaquin, Avodart, and Uroxatral Pose a Threat to Market Revenues 23
3.4.3 Non Pharmacological Therapy Recommended for UI and BPH 23
4 Global Urological Disorders Market: Therapeutic Landscape 24
4.1 Benign Prostatic Hyperplasia Market 24
4.1.1 Introduction 24
4.1.2 Sales Value 24
4.1.3 Annual Cost of Therapy 26
4.1.4 Treatment Usage Patterns 27
4.1.5 Market Share by Geography 32
4.1.6 Generics’ Share of the Global BPH Market 35
4.2 Urinary Incontinence (UI) Market 36
4.2.1 Introduction 36
4.2.2 Sales Value 37
4.2.3 Annual Cost of Therapy 39
4.2.4 Treatment Usage Patterns 40
4.2.5 Market Share by Geography 45
4.2.6 Generics’ Share in the Global UI Market 49
4.3 Urinary Tract Infections Market 51
4.3.1 Introduction 51
4.3.2 Sales Value 51
4.3.3 Annual Cost of Therapy 53
4.3.4 Treatment Usage Patterns 54
4.3.5 Market Share by Geography 59
4.3.6 Generics’ Share of the Global UTI Market 62
5 Global Urological Disorders Market: Geographical Landscape 64
5.1 Geographical Break-up 64
5.2 The US 67
5.2.1 Sales Value 67
5.2.2 Annual Cost of Therapy 68
5.2.3 Treatment Usage Patterns 69
5.3 Top Five Countries in Europe 75
5.3.1 Sales Value 75
5.3.2 Annual Cost of Therapy 76
5.3.3 Treatment Usage Patterns 77
5.4 Japan 83
5.4.1 Sales Value 83
5.4.2 Annual Cost of Therapy 84
5.4.3 Treatment Usage Patterns 85
6 Global Urological Disorders Market: Pipeline Analysis 90
6.1 Introduction 90
6.1.1 Research and Development Pipeline – UI 91
6.1.2 Research and Development Pipeline – BPH 93
6.1.3 Research and Development Pipeline – UTI 95
6.2 Profiles of Key Late-Stage Drugs in the Urological Disorders Market 97
6.2.1 Botulinum Toxin A 97
6.2.2 YM178 98
6.2.3 NX-1207 98
6.2.4 PRX302 99
6.2.5 NXL104/ceftazidime 100
7 Global Urological Disorders Market: Competitive Landscape 101
7.1 Market Share Analysis: Urological Disorders 101
7.2 Competitive Profiling 103
7.2.1 Astellas Pharma 103
7.2.2 Johnson and Johnson (J&J) 104
7.2.3 Pfizer 106
7.2.4 GlaxoSmithKilne (GSK) 107
7.2.5 Sanofi-Aventis 108
8 Global Urological Disorders Market: Strategic Consolidations 110
8.1 Overview 110
8.1.1 Warner Chilcott Acquires Prescription Drug Business of Procter & Gamble in October 2009 112
8.1.2 Actavis Group Acquires Floxapen from GlaxoSmithKline in May 2007 112
8.1.3 Biofusion Acquires Minority Stake in Muscagen in November 2006 112
8.1.4 Eli Lilly Reacquires Rights to Yentreve from Boehringer Ingelheim in February 2006 112
8.1.5 Odyssey Pharmaceuticals Sells SANCTURA to Esprit Pharma in May 2005 112
8.1.6 Ardana Bioscience Acquires Rights to Teverelix from AEterna Zentaris in April 2004 112
8.2 R&D Licensing Agreements 113
8.2.1 Deals by Indication 113
8.2.2 Deals by Phase 114
8.2.3 Deals by Geography 114
8.2.4 Deals by Licensing Type 115
8.2.5 Deals by Value ($) 115
8.2.6 Phase I 116
8.2.7 Phase II 117
8.2.8 Approved 118
9 Global Urological Disorders Market: Appendix 120
9.1 Market Definitions 120
9.2 Abbreviations 120
9.3 Research Methodology 121
9.3.1 Coverage 121
9.3.2 Secondary Research 121
9.3.3 Primary Research 122
9.3.4 Forecasts 122
9.3.5 Expert Panel Validation 124
9.4 Contact Us 125
9.5 Disclaimer 125
9.6 Sources 125

1.1 List of Tables
Table 1: Urological Disorders Market, Global, Sales Value ($bn), 2001–2009 13
Table 2: Urological Disorders Market, Global, Sales Value ($bn), 2009–2016 13
Table 3: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2001–2009 14
Table 4: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2009–2016 15
Table 5: Urological Disorders Market, Global, Treatment Usage Patterns (million), 2001–2009 16
Table 6: Urological Disorders Market, Global, Treatment Usage Patterns (million), 2009–2016 16
Table 7: Urological Disorders Market, Global, Branded Vs Generic Drugs ($bn), 2001–2009 21
Table 8: Urological Disorders Market, Global, Branded Vs Generic Drugs ($bn), 2009–2016 21
Table 9: Urological Disorders Market, Global, BPH Sales Value ($bn), 2001–2009 25
Table 10: Urological Disorders Market, Global, BPH Sales Value ($bn), 2009–2016 25
Table 11: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2001–2009 26
Table 12: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2009–2016 27
Table 13: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2001–2009 27
Table 14: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2009–2016 28
Table 15: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2001–2009 33
Table 16: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2009–2016 34
Table 17: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2001–2009 35
Table 18: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2009–2016 36
Table 19: Urological Disorders Market, Global, UI Sales Value ($bn), 2001–2009 38
Table 20: Urological Disorders Market, Global, UI Sales Value ($bn), 2009–2016 38
Table 21: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2001–2009 39
Table 22: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2009–2016 39
Table 23: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2001–2009 40
Table 24: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2009–2016 41
Table 25: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2001–2009 47
Table 26: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2009–2016 47
Table 27: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2001–2009 49
Table 28: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2009–2016 50
Table 29: Urological Disorders Market, Global, UTI Sales Value ($bn), 2001–2009 52
Table 30: Urological Disorders Market, Global, UTI Sales Value ($bn), 2009–2016 52
Table 31: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2001–2009 53
Table 32: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2009–2016 53
Table 33: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2001–2009 54
Table 34: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2009–2016 55
Table 35: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2001–2009 60
Table 36: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2009–2016 61
Table 37: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2001–2009 62
Table 38: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2009–2016 62
Table 39: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2001–2009 65
Table 40: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2009–2016 65
Table 41: Urological Disorders Market, US, Sales Value ($bn), 2001–2009 67
Table 42: Urological Disorders Market, US, Sales Value ($bn), 2009–2016 68
Table 43: Urological Disorders Market, US, Annual Cost of Therapy ($), 2001–2009 68
Table 44: Urological Disorders Market, US, Annual Cost of Therapy ($), 2009–2016 69
Table 45: Urological Disorders Market, US, Treatment Usage Patterns (million), 2001–2009 70
Table 46: Urological Disorders Market, US, Treatment Usage Patterns (million), 2009–2016 70
Table 47: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2009 75
Table 48: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2009–2016 76
Table 49: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2009 77
Table 50: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2009–2016 77
Table 51: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2001–2009 78
Table 52: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Pattern (million), 2009–2016 78
Table 53: Urological Disorders Market, Japan, Sales Value ($bn), 2001–2009 83
Table 54: Urological Disorders Market, Japan, Sales Value ($bn), 2009–2016 84
Table 55: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2009 84
Table 56: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2009–2016 84
Table 57: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2009 85
Table 58: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2009–2016 86
Table 59: Urological Disorders Market, Global, R&D Pipeline by Phase in UI Market, AUG 2010 92
Table 60: Urological Disorders Market, Global, R&D Pipeline by Phase in BPH Market, AUG 2010 94
Table 61: Urological Disorders Market, Global, R&D Pipeline by Phase in UTI Market, AUG 2010 96
Table 62: Urological Disorders Market, Global, Major M&A Deals, 2004-2009 111
Table 63: Urological Disorders Market, Global, Licensing Agreements for Drugs in Phase I Stage, 2004 116
Table 64: Urological Disorders Market, Global, Licensing Agreements for Drugs in Phase II Stage, 2004–2010 117
Table 65: Urological Disorders Market, Global, Licensing Agreements for Approved Drugs, 2008–2010 118

1.2 List of Figures
Figure 1: Urological Disorders Market, Global, Drivers and Restraints, 2009 11
Figure 2: Urological Disorders Market, Global, Sales Value ($bn), 2001–2016 12
Figure 3: Urological Disorders Market, Global, Annual Cost of Therapy ($), 2001–2016 13
Figure 4: Urological Disorders Market, Global, Therapeutic Usage Patterns (million), 2001–2016 14
Figure 5: Urological Disorders Market, Global, Diseased Population (million), 2001–2016 16
Figure 6: Urological Disorders Market, Global, Treatment Seeking Population (million), 2001–2016 17
Figure 7: Urological Disorders Market, Global, Diagnosis Population (million), 2001–2016 18
Figure 8: Urological Disorders Market, Global, Prescription Population (million), 2001–2016 19
Figure 9: Urological Disorders Market, Global, Branded Vs Generics ($bn), 2001–2016 20
Figure 10: Urological Disorders Market, Global, Market Indicators, 2009 21
Figure 11: Urological Disorders Market, Global, BPH Sales Value ($bn), 2001–2016 24
Figure 12: Urological Disorders Market, Global, BPH Annual Cost of Therapy ($), 2001–2016 25
Figure 13: Urological Disorders Market, Global, BPH Treatment Usage Patterns (million), 2001–2016 26
Figure 14: Urological Disorders Market, Global, BPH Diseased Population (million), 2001–2016 27
Figure 15: Urological Disorders Market, Global, BPH Treatment Seeking Population (million), 2001–2016 28
Figure 16: Urological Disorders Market, Global, BPH Diagnosis Population (million), 2001–2016 29
Figure 17: Urological Disorders Market, Global, BPH Prescription Population (million), 2001–2016 30
Figure 18: Urological Disorders Market, Global, BPH Market Segmentation by Geography (%), 2009 and 2016 31
Figure 19: Urological Disorders Market, Global, BPH Market in the Top Five Countries in Europe (%), 2009 and 2016 31
Figure 20: Urological Disorders Market, Global, BPH Market Geographical Segmentation ($bn), 2001–2016 32
Figure 21: Urological Disorders Market, Global, BPH Market, Geography Benchmarking, 2009 33
Figure 22: Urological Disorders Market, Global, BPH Branded Vs Generics ($bn), 2001–2016 34
Figure 23: Urological Disorders Market, Global, BPH Market, Generics Share (%), 2009 and 2016 35
Figure 24: Urological Disorders Market, Global, UI Sales Value ($bn), 2001–2016 37
Figure 25: Urological Disorders Market, Global, UI Annual Cost of Therapy ($), 2001–2016 38
Figure 26: Urological Disorders Market, Global, UI Treatment Usage Patterns (million), 2001–2016 39
Figure 27:Urological Disorders Market, Global, UI Diseased Population (million), 2001–2016 40
Figure 28:Urological Disorders Market, Global, UI Treatment Seeking Population (million), 2001–2016 41
Figure 29:Urological Disorders Market, Global, UI Diagnosis Population (million), 2001–2016 42
Figure 30: Urological Disorders Market, Global, UI Prescription Population (million), 2001–2016 43
Figure 31: Urological Disorders Market, Global, UI Market Segmentation by Geography (%), 2009 and 2016 44
Figure 32: Urological Disorders Market, Global, UI Market in the Top Five Countries in Europe (%), 2009 and 2016 44
Figure 33: Urological Disorders Market, Global, UI Market Geographical Segmentation ($bn), 2001–2016 45
Figure 34: Urological Disorders Market, Global, UI Market, Geography Benchmarking, 2009 47
Figure 35: Urological Disorders Market, Global, UI Branded Vs Generics ($m), 2001–2016 48
Figure 36: Urological Disorders Market, Global, UI Market, Generics Share (%), 2009 and 2016 49
Figure 37: Urological Disorders Market, Global, UTI Sales Value ($bn), 2001–2016 51
Figure 38: Urological Disorders Market, Global, UTI Annual Cost of Therapy ($), 2001–2016 52
Figure 39: Urological Disorders Market, Global, UTI Treatment Usage Patterns (million), 2001–2016 53
Figure 40: Urological Disorders Market, Global, UTI Diseased Population (million), 2001–2016 54
Figure 41: Urological Disorders Market, Global, UTI Treatment Seeking Population (million), 2001–2016 55
Figure 42: Urological Disorders Market, Global, UTI Diagnosis Population (million), 2001–2016 56
Figure 43: Urological Disorders Market, Global, UTI Prescription Population (millions), 2001–2016 57
Figure 44: Urological Disorders Market, Global, UTI Market Segmentation by Geography (%), 2009 and 2016 58
Figure 45: Urological Disorders Market, Global, UTI Market Geographical Segmentation ($bn), 2001–2016 59
Figure 46: Urological Disorders Market, Global, UTI Market, Geography Benchmarking, 2009 60
Figure 47: Urological Disorders Market, Global, UTI Branded Vs Generics ($bn), 2001–2016 61
Figure 48: Urological Disorders Market, Global, UTI Market, Generics Share (%), 2009 and 2016 62
Figure 49: Urological Disorders Market, Global, Market Share by Geography (%), 2009 and 2016 63
Figure 50: Urological Disorders Market, Global, Sales Value by Geography ($bn), 2001–2016 64
Figure 51: Urological Disorders Market, Global, Geography Benchmarking, 2009 and 2016 65
Figure 52: Urological Disorders Market, US, Sales Value ($bn), 2001–2016 66
Figure 53: Urological Disorders Market, US, Annual Cost of Therapy ($), 2001–2016 67
Figure 54: Urological Disorders Market, US, Treatment Usage Patterns (million), 2001–2016 69
Figure 55: Urological Disorders Market, US, Diseased Population (million), 2001–2016 70
Figure 56: Urological Disorders Market, US, Treatment Seeking Population (million), 2001–2016 71
Figure 57: Urological Disorders Market, US, Diagnosis Population (million), 2001–2016 72
Figure 58: Urological Disorders Market, US, Prescription Population (million), 2001–2016 73
Figure 59: Urological Disorders Market, Top Five Countries in Europe, Sales Value ($bn), 2001–2016 74
Figure 60: Urological Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2001–2016 75
Figure 61: Urological Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2001–2016 76
Figure 62: Urological Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2001–2016 78
Figure 63: Urological Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2001–2016 79
Figure 64: Urological Disorders Market, Top Five Countries in Europe, Diagnosis Population (million), 2001–2016 80
Figure 65: Urological Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2001–2016 81
Figure 66: Urological Disorders Market, Japan, Sales Value ($bn), 2001–2016 82
Figure 67: Urological Disorders Market, Japan, Annual Cost of Therapy ($), 2001–2016 83
Figure 68: Urological Disorders Market, Japan, Treatment Usage Pattern (million), 2001–2016 84
Figure 69: Urological Disorders Market, Japan, Diseased Population (million), 2001–2016 85
Figure 70: Urological Disorders Market, Japan, Treatment Seeking Population (million), 2001–2016 86
Figure 71: Urological Disorders Market, Japan, Diagnosed Population (million), 2001–2016 87
Figure 72: Urological Disorders Market, Japan, Prescription Population (million), 2001–2016 88
Figure 73: Urological Disorders Market, Global, R&D Pipeline by Indication (%), AUG 2010 89
Figure 74: Urological Disorders Market, Global, R&D Pipeline by Phase (%), AUG 2010 90
Figure 75: Urological Disorders Market, Global, R&D Pipeline by Phase in UI Market (%), AUG 2010 92
Figure 76: Urological Disorders Market, Global, R&D Pipeline by Phase in BPH Market (%), AUG 2010 94
Figure 77: Urological Disorders Market, Global, R&D Pipeline by Phase in UTI Market (%), AUG 2010 95
Figure 78: Urological Disorders Market, Global, Market Share of Top Manufacturers (%), 2009 100
Figure 79: Urological Disorders Market, Global, Revenue of Top Five Players ($m), 2007–2009 101
Figure 80: Urological Disorders Market, Global, Competitive Analysis of Top Five Players, Market Share and CAGR (%), 2007–2009 102
Figure 81: Urological Disorders Market, Global, SWOT- Astellas Pharma, 2010 103
Figure 82: Urological Disorders Market, Global, SWOT- Johnson & Johnson, 2010 105
Figure 83: Urological Disorders Market, Global, SWOT- Pfizer, 2010 106
Figure 84: Urological Disorders Market, Global, SWOT- GlaxoSmithKline, 2010 107
Figure 85: Urological Disorders Market, Global, SWOT- Sanofi-Aventis, 2010 108
Figure 86: Urological Disorders Market, Global, M&A Deals by Indication (%), 2009 109
Figure 87: Urological Disorders Market, Global, Major Licensing Agreements By Indication (%), 2004–2010 112
Figure 88: Urological Disorders Market, Global, Major Licensing Agreements By Phase (%), 2005–2010 113
Figure 89: Urological Disorders Market, Global, Major Licensing Agreements By Geography (%), 2004–2010 113
Figure 90: Urological Disorders Market, Global, Major Licensing Agreements By Licensing Type (%), 2004–2010 114
Figure 91: Urological Disorders Market, Global, Major Licensing Agreements By Deal Value (%), 2004–2010 114
Figure 92: GBI Research Market Forecasting Model 123

Companies mentioned
Astellas Pharma
Johnson and Johnson (J&J)
Pfizer
GlaxoSmithKilne (GSK)
Sanofi-Aventis

Talk to Alison

00 1 718 618 48 97

Send Your Request

Follow

Add to circles Subscribe to our RSS feeds!

Global Therapy Industry : Latest Reports

OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017

$ 5 995
Industry report
April 2013
by Global Data

OpportunityAnalyzer: Idiopathic Pulmonary Fibrosis (IPF) - Opportunity Analysis and Forecasts to 2017 Summary Idiopathic Pulmonary fibrosis (IPF) is a chronic, progressive fibrosing interstitial pneumonia ...

Analytical Tool - Protein Kinase Inhibitors in Oncology

$ 6 674
Industry report
April 2013
by Bioseeker

Analytical Tool - Protein Kinase Inhibitors in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in the drug development of protein kinase inhibitors ...

Personalized Medicine Partnering Terms and Agreements

$ 4 995
Industry report
April 2013
by Currentpartnering

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The Personalized Medicine Partnering ...

Peptide Therapeutics Market - Global Indus ...

March 2013 $ 4 595

Clinical Stage Partnering Terms And Agreem ...

April 2013 $ 2 995

Ocular Hypertension Global Clinical Trials ...

February 2013 $ 2 500

Drug And Medication Industry: Hiv / Aids - ...

February 2013 $ 2 500

Dental Pain Global Clinical Trials Review, ...

February 2013 $ 2 500

Cancer Pain Global Clinical Trials Review, ...

April 2013 $ 2 500

Osteoarthritis Pain Global Clinical Trials ...

April 2013 $ 2 500

More Reports:

Therapy in Canada (24)

Therapy in France (43)

Therapy in Germany (46)

Therapy in Italy (45)

Therapy in Japan (54)

Therapy in Spain (44)

Therapy in the United Kingdom (44)

Therapy in the United States (114)

Company Reports

Novartis Inc.

Pfizer Inc.

GlaxoSmithKline P.L.C.

GlaxoSmithKline PLC

Teva Pharmaceutical Industries Ltd.

Bristol-Myers Squibb Co.

Johnson And Johnson

Sanofi-Aventis Senegal

Amgen Inc.

Bayer AG

Global Therapy Industry : Latest Downloads

Global Therapy Sector Overview

Industry report
May 2013
22 pages

... Medicine: definition 2 The tailoring of medical treatment to the specific characteristics of each patient. [It] does not literally mean the creation of drugs or medical devices that are unique ...

World Liver Diseases Therapeutics : Innovation and Technology Trends

Industry report
January 2013
12 pages

... Portfolio and recent developments is also provided in the report. Transparency market research liver diseases therapeutics market - global industry analysis, size, share, trends ...

Therapy : Innovation and Technology Trends